GALE.SW Galenica AG (SIX) Q1 earnings 10 Mar 2026: margins and guidance in focus

GALE.SW stock trades at CHF 94.75 as Galenica AG prepares to report Q1 results on 10 Mar 2026 intraday. Investors will focus on margins, pharmacy sales and Logistics & IT trends. The group shows EPS CHF 3.86 and PE 24.33, with market cap at CHF 4,678,757,272.00. We track guidance, same-store pharmacy sales, and cash flow versus expectations.

GALE.SW stock: earnings snapshot and calendar

Galenica reports Q1 on 10 Mar 2026 with the earnings announcement scheduled intraday. Current consensus metrics include EPS 3.86 and PE 24.33, which frame expectations for profit growth. Watch management comments on revenue mix between Products & Care and Logistics & IT, and any update to fiscal guidance.

GALE.SW stock: financials and valuation metrics

Galenica trades at P/S 1.16 and P/B 3.24, with dividend per share at CHF 2.30 and yield about 2.45%. Free cash flow per share is CHF 5.98, and debt to equity is 0.60. These ratios show a defensive healthcare profile with moderate valuation versus Swiss peers.

GALE.SW stock: operational drivers and sector context

Galenica operates 520 pharmacies and a Logistics & IT arm serving Swiss healthcare. Pharmacy volumes drive Products & Care margins. In the Healthcare sector, Galenica’s margins lag large drugmakers but beat small distributors. Sector pressure and consumer health trends will shape near-term sales and pricing power.

GALE.SW stock: intraday price action and technicals

Intraday range is CHF 92.55–95.75 with volume 57,457 versus average 108,500. RSI sits at 33.42, signaling near-term weakness. Bollinger middle band is CHF 98.44, lower band CHF 91.45. A close above CHF 98.07 (50-day average) would reduce short-term downside risk.

GALE.SW stock: Meyka AI grade and model forecast

Meyka AI rates GALE.SW with a score out of 100: 75.77 — Grade B+ (BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year target CHF 110.34, implying an upside of 16.44% from CHF 94.75. Forecasts are model-based projections and not guarantees.

GALE.SW stock: catalysts, risks and what to watch

Key catalysts include Q1 same-store sales, Logistics contract renewals, and margin commentary. Watch free cash flow conversion and dividend sustainability given payout ratio 59.70%. Risks are margin pressure, slower consumer health growth, and net debt to EBITDA near 2.34 which limits flexibility.

Final Thoughts

Galenica’s Q1 report on 10 Mar 2026 matters for GALE.SW stock because margins and guidance will set the tone for the year. At CHF 94.75, valuation shows a PE 24.33 and dividend yield 2.45%, balancing income and modest growth. Meyka AI’s forecast model projects CHF 110.34 in 12 months, an implied upside of 16.44%, but the model is not a guarantee. Traders should watch same-store sales, Logistics & IT margins, and management guidance. For longer-term investors, cash flow per share CHF 5.98 and a stable payout support a buy-if-earnings beat; missed guidance would pressure the stock toward the 50-day average CHF 98.07 or lower support at CHF 90.35. Use intraday volume and RSI to time entries while referencing the company site and our Meyka market page for live updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.